Incidence of Hypogammaglobulinemia in Patients Receiving Rituximab and the Use of Intravenous Immunoglobulin for Recurrent Infections

CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

Bertrand Coiffier, Éric Lepage, Josette Brière et al. · New England Journal of Medicine · 2002 · 5.6K citations · Full text

Medicine, Immunology, Oncology +9

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Peter McLaughlin, A.J. Grillo-López, Brian K. Link et al. · Journal of Clinical Oncology · 1998 · 2.8K citations

Pharmacy, Hematology, Immunology +17

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

Michael Pfreundschuh, Lorenz Trümper, Anders Österborg et al. · The Lancet Oncology · 2006 · 2.1K citations

Medicine, Oncology, Chemotherapy +11

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

Michael Hallek, Kirsten Fischer, Guenter Fingerle-Rowson et al. · The Lancet · 2010 · 1.9K citations

Medicine, Oncology, Pharmacotherapy +10

IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

David G. Maloney, Antonio J Grillo-López, Christine A. White et al. · Blood · 1997 · 1.7K citations

Medicine, Hematology, Oncology +14